替米沙坦联合干扰素治疗对慢性乙肝患者肝纤维化的影响

发布时间：2019-01-23 20:19

【摘要】：目的:探讨替米沙坦联合干扰素治疗对慢性乙肝患者肝纤维化的影响。方法:选取既往未行抗病毒治疗的HBVDNA阳性的慢性乙肝患者50例,随机分为观察组及对照组。对照组予以普通干扰素治疗,观察组在普通干扰素治疗的基础上加用替米沙坦80 mg口服,每日一次。治疗周期48周。治疗前后分别行血清肝纤维化指标及肝脏组织病理学检查,并通过免疫组化方法测定TGF-β1、TIMP-1、MMP-1及α-SMA的表达及含量。结果:治疗后,观察组及对照组血清肝纤维化指标(HA、Ⅳ-C、LN、PIIIP)、肝纤维化分级水平及肝纤维化半定量计分较治疗前均下降,且观察组下降更明显,治疗前后,观察组和对照组肝组织中TGF-β1、TIMP-1及α-SMA表达水平明显下降,MMP-1水平明显升高,以观察组变化更为显著。结论:干扰素抗病毒的同时有抗肝纤维化作用,加用替米沙坦后抗肝纤维化作用更明显,提示替米沙坦与干扰素有协同抗纤维化作用。
[Abstract]:Objective: to investigate the effect of telmisartan combined with interferon on hepatic fibrosis in patients with chronic hepatitis B. Methods: 50 patients with HBVDNA positive hepatitis B were randomly divided into observation group and control group. The control group was treated with common interferon, and the observation group was treated with telmisartan 80 mg orally once a day. The treatment period was 48 weeks. Serum hepatic fibrosis index and liver histopathology were examined before and after treatment, and the expression and content of MMP-1 and 伪-SMA in TGF- 尾 1 TIMP-1 and 伪-SMA were determined by immunohistochemical method. Results: after treatment, serum hepatic fibrosis index (HA, 鈪，

本文编号：2414156